Pfizer Medications - Search News

Pfizer to acquire obesity drug startup Metsera

Pfizer Wins Obesity Drug Battle, With Assist by Trump’s FTC

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize.

· 3d

Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

· 3d · on MSN

Pfizer wins $10B bidding war for obesity drug developer Metsera in major pharmaceutical acquisition

· 1d

Pfizer shows hardball mettle needed to win in 2025 M&A

On September 22, Pfizer announced a deal to acquire the shares of promising weight-loss drug start-up Metsera for $5.5bn.

· 23h

Metsera shares fall as Pfizer-Novo Nordisk bidding war comes to an end

· 1d

Novo Nordisk stock rises as drugmaker drops out of bidding war for Metsera

1don MSN

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration

Becker's Hospital Review

The Trump administration’s drug pricing deals, explained

Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.

1hon MSN

Where Will Pfizer Be in 3 Years?

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Fierce Biotech

With Summit leading the pack in PD-1xVEGF bispecifics, Pfizer lays out its own plan to replace Keytruda

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its